Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases

Wakabayashi, Hiroshi; Nakajima, Kénichi; Mizokami, Atsushi; Namiki, Mikio; Inaki, Anri; Taki, Junichi; Kinuya, Seigo

doi:10.1007/s12149-013-0749-x

Cited by 46 publications

(33 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even in a phase II study in Japan using Ra‐223, the mean change rate of PSA by Ra‐223 was rather increased to 97.3% and 230.5%, although the mean change rate of Alp was −19.3% and −1.9% at 12 weeks after the first treatment and 4 weeks after the final treatment, respectively. We experienced the case that PSA continued being elevated, although bone‐derived Alp and BSI on bone scintigraphy were improved by Ra‐223 . It remains unclear why such a discrepancy occurs by Ra‐223.…”

Section: Border Attack By Ra‐223mentioning

confidence: 99%

Therapies for castration‐resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines

et al. 2017

Self Cite

View full text Add to dashboard Cite

Abbreviations & Acronyms AIPC = androgenindependent prostate cancer AR = androgen receptor AR-V7 = androgen receptor splice variant 7 BSC = best supportive care BSI = Bone Scan Index CAB = combined androgen blockade CRPC = castration-resistant prostate cancer HHSPC = hormonehypersensitive prostate cancer PFS = progression-free survival PSA = prostate-specific antigen Ra-223 = radium-223 Abstract: When advanced prostate cancer recurred during hormonal therapy and became the castration-resistant prostate cancer, "vintage hormonal therapy," such as antiandrogen alternating therapy or estrogen-related hormonal therapy, was widely carried out in Japan until 2013. This vintage hormonal therapy controlled the progression of castration-resistant prostate cancer. When castration-resistant prostate cancer relapses during these therapies, chemotherapy using docetaxel has been carried out subsequently. Since new hormonal therapies using abiraterone acetate and enzalutamide, which improve the prognosis of castration-resistant prostate cancer, became available in Japan from 2014, therapeutic options for castration-resistant prostate cancer have increased. Furthermore, the improvement of the further prognosis is promising by using cabazitaxel for docetaxel-resistant castration-resistant prostate cancer and radium-223 for castration-resistant prostate cancer with bone metastasis. An increase in therapeutic options gives rise to many questions, including best timing to use them and the indication. Furthermore, physicians have to consider the treatment for the recurrence after having carried out chemotherapy. We want to argue the difference in hormonal therapy between Japan and Western countries, and problems when carrying out new treatments, and the importance of imaging in the present review article.

show abstract

Section: Border Attack By Ra‐223mentioning

confidence: 99%

Therapies for castration‐resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Skeletal scintigrams were performed in two other studies and different bone markers determined: BAP, ICTP, and TRAP5b [146] or rather BAP, OC, PICP, PINP, NTX, and CTX [76]. BAP correlated best with the extent of osseous changes (bone scan index) and had the greatest diagnostic accuracy (72% sensitivity, 88% specificity).…”

Section: Bone Markers In Diagnosticsmentioning

confidence: 99%

Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis

Jung

Lein

2014

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

“…The BSI can evaluate therapeutic courses including hormonal therapy and chemotherapy, and could thus serve as a biomarker of bone metastasis instead of various chemical markers of bone and tumor markers. The BSI closely correlates with the bone metabolic markers, pyridinoline cross‐linked carboxy‐terminal telopeptide of type I collagen, bone alkaline phosphatase and tartrate‐resistant acid phosphatase‐5b, and the correlation is closest with log (bone alkaline phosphatase) . In contrast, the correlation with PSA is only fair.…”

Section: Bsi For Diagnosis and Treatmentmentioning

confidence: 95%

Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer

2017

Self Cite

View full text Add to dashboard Cite

Bone scintigraphy is one of the first-line imaging modalities for the screening and follow up of bone metastasis in patients with prostate cancer. The amount (%) of bone metastasis can be calculated using a bone scan index thanks to recent advances in quantitative bone scintigraphy. Since an artificial neural network was applied for hot-spot characterization and quantitation, the bone scan index has become a simple, reproducible and practical means of quantifying bone metastasis. The bone scan index is presently considered as an imaging biomarker of bone metastasis. The present article summarizes the principles and application of bone scan index using dedicated software (EXINI bone in Europe and North America; BONENAVI in Japan), and the advantages and cautions of using the bone scan index. The bone scan index could serve as a practical marker with which to monitor disease progression and treatment effects in multicenter studies, and to manage prostate and other types of cancer in the clinical setting.

show abstract

Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases

Abstract: The changes in BSI showed a close relationship with all bone metabolic markers but not with the serum PSA. The BSI is confirmed to reflect the activity and extent of bone metastases, and can be used as an imaging biomarker.

Cited by 46 publications

References 18 publications

Therapies for castration‐resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines

Therapies for castration‐resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines

Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis

Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer

Contact Info

Product

Resources

About